Mourad Topors
Company: Repair Biotechnologies
Job title: Chief Scientific Officer
Seminars:
Enzymatic Clearance of Excess Free Cholesterol Reduces NASH Pathology in Models of Disease 10:00 am
Excess intracellular free cholesterol is hypothesized to drive NASH pathology Developing a LNP-mRNA therapy that expresses a cholesterol-degrading fusion protein in the liver 4 to 8 weeks of weekly dosing with the Repair Biotechnologies therapy significantly reduces NASH associated biomarkers and histology in mouse models of diseaseRead more
day: Conference Day 1